A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma
Clinical Journal of Gastroenterology · 2024
DOI: 10.1007/s12328-024-02040-8 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Journal of Gastroenterology, 2024. Verfasst von Hisashi Hidaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Kitasato University Hospital, 1-15-1 Kitasato, Minami-Ku, …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
A woman in the 70s with a decreased appetite and weight loss (4 kg) in the last 3 months was referred to our hospital. An enhanced CT scan of the abdomen showed a hepatocellular carcinoma (HCC) of 83 mm in diameter of the liver with metastasis to the para-aortic lymph nodes, the left adrenal gland, and the right lower lung lobe (cStage IVb). She was started on atezolizumab + bevacizumab (Atezo-Bev) therapy. A week after the treatment, she began to have a decreased appetite, fever in the 39 °C range, subcutaneous bleeding, and a slight headache when walking. So she was urgently admitted to our hospital. We diagnosed her as having a hemophagocytic syndrome and administered 1 g steroid pulse therapy for 3 days followed by 1 mg/kg of prednisone. Her condition began to improve. This is the first case report of a hemophagocytic syndrome in a patient with HCC treated with Atezo-Bev.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Kitasato University Hospital, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan. hisashi7@kitasato-u.ac.jp.
- Department of Hematology, Kitasato University School of Medicine, Kanagawa, Japan.
- Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Kitasato University Hospital, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Zitieren
APA
Hidaka, H., Kamata, H., Uojima, H., Iwasaki, S., Iida, J., Nakazawa, T., & Kusano, C. (2024). A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-024-02040-8
Vancouver
Hidaka H, Kamata H, Uojima H, Iwasaki S, Iida J, Nakazawa T, et al. A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology. 2024. doi:10.1007/s12328-024-02040-8
BibTeX
@article{Hidaka2024,
author = {Hidaka, Hisashi and Kamata, Hirotoshi and Uojima, Haruki and Iwasaki, Shuichiro and Iida, Junki and Nakazawa, Takahide and Kusano, Chika},
title = {A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma},
journal = {Clinical Journal of Gastroenterology},
year = {2024},
doi = {10.1007/s12328-024-02040-8}
}
EUVIMED